Review Article| Volume 18, ISSUE 2, P223-231, April 2023

Diagnosis and Treatment of Lung Neuroendocrine Neoplasms

Somatostatin Receptor PET Imaging and Peptide Receptor Radionuclide Therapy
Published:December 28, 2022DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Shah S.
        • Gosain R.
        • Groman A.
        • et al.
        Incidence and survival outcomes in patients with lung neuroendocrine neoplasms in the United States.
        Cancers (Basel). 2021; 13
        • Swarts D.R.
        • Rudelius M.
        • Claessen S.M.
        • et al.
        Limited additive value of the Ki-67 proliferative index on patient survival in World Health Organization-classified pulmonary carcinoids.
        Histopathology. 2017; 70: 412-422
      1. WHO classification of Tumours Editorial Board, WHO classification of Tumours - Thoracic tumors, 5.

        • Pelosi G.
        • Rindi G.
        • Travis W.D.
        • et al.
        Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice.
        J Thorac Oncol. 2014; 9: 273-284
        • Meisinger Q.C.
        • Klein J.S.
        • Butnor K.J.
        • et al.
        CT features of peripheral pulmonary carcinoid tumors.
        AJR Am J Roentgenol. 2011; 197: 1073-1080
        • Caplin M.E.
        • Baudin E.
        • Ferolla P.
        • et al.
        Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids.
        Ann Oncol. 2015; 26: 1604-1620
        • Dermawan J.K.
        • Farver C.F.
        The prognostic significance of the 8th edition TNM staging of pulmonary carcinoid tumors: a single institution study with long-term follow-up.
        Am J Surg Pathol. 2019; 43: 1291-1296
        • Yoon J.Y.
        • Sigel K.
        • Martin J.
        • et al.
        Evaluation of the prognostic significance of TNM staging guidelines in lung carcinoid tumors.
        J Thorac Oncol. 2019; 14: 184-192
        • Righi L.
        • Volante M.
        • Tavaglione V.
        • et al.
        Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
        Ann Oncol. 2010; 21: 548-555
        • Chiaravalloti A.
        • Spanu A.
        • Danieli R.
        • et al.
        111In-Pentetreotide SPECT/CT in pulmonary carcinoid.
        Anticancer Res. 2015; 35: 4265-4270
        • Prasad V.
        • Steffen I.G.
        • Pavel M.
        • et al.
        Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids.
        EJNMMI Res. 2015; 5: 53
        • Fallahi B.
        • Manafi-Farid R.
        • Eftekhari M.
        • et al.
        Diagnostic fficiency of (68)Ga-DOTATATE PET/CT as ompared to (99m)Tc-Octreotide SPECT/CT andonventional orphologic odalities in euroendocrine umors.
        Asia Ocean J Nucl Med Biol. 2019; 7: 129-140
        • Jiang Y.
        • Hou G.
        • Cheng W.
        Performance of 68Ga-DOTA-SST PET/CT, octreoscan SPECT/CT and 18F-FDG PET/CT in the detection of culprit tumors causing osteomalacia: a meta-analysis.
        Nucl Med Commun. 2020; 41: 370-376
        • Deppen S.A.
        • Blume J.
        • Bobbey A.J.
        • et al.
        68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis.
        J Nucl Med. 2016; 57: 872-878
        • Deleu A.L.
        • Laenen A.
        • Decaluwé H.
        • et al.
        Value of [(68)Ga]Ga-somatostatin receptor PET/CT in the grading of pulmonary neuroendocrine (carcinoid) tumours and the detection of disseminated disease: single-centre pathology-based analysis and review of the literature.
        EJNMMI Res. 2022; 12: 28
        • Moore W.
        • Freiberg E.
        • Bishawi M.
        • et al.
        FDG-PET imaging in patients with pulmonary carcinoid tumor.
        Clin Nucl Med. 2013; 38: 501-505
        • Jiang Y.
        • Hou G.
        • Cheng W.
        The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: a systematic review and meta-analysis.
        Medicine (Baltimore). 2019; 98: e14769
        • Mamede M.
        • Higashi T.
        • Kitaichi M.
        • et al.
        [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung.
        Neoplasia. 2005; 7: 369-379
        • Ozbudak I.H.
        • Shilo K.
        • Tavora F.
        • et al.
        Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis.
        Mod Pathol. 2009; 22: 633-638
        • Chan D.L.
        • Pavlakis N.
        • Schembri G.P.
        • et al.
        Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance.
        Theranostics. 2017; 7: 1149-1158
        • Alevroudis E.
        • Spei M.E.
        • Chatziioannou S.N.
        • et al.
        Clinical utility of (18)F-FDG PET in neuroendocrine tumors prior to peptide receptor radionuclide therapy: a systematic review and meta-analysis.
        Cancers (Basel). 2021; 13
        • Binderup T.
        • Knigge U.
        • Johnbeck C.B.
        • et al.
        (18)F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study.
        J Nucl Med. 2021; 62: 808-815
        • Zidan L.
        • Iravani A.
        • Kong G.
        • et al.
        Theranostic implications of molecular imaging phenotype of well-differentiated pulmonary carcinoid based on (68)Ga-DOTATATE PET/CT and (18)F-FDG PET/CT.
        Eur J Nucl Med Mol Imaging. 2021; 48: 204-216
        • Detterbeck F.C.
        Management of carcinoid tumors.
        Ann Thorac Surg. 2010; 89: 998-1005
        • Ramirez R.A.
        • Thomas K.
        • Jacob A.
        • et al.
        Adjuvant therapy for lung neuroendocrine neoplasms.
        World J Clin Oncol. 2021; 12: 664-674
        • Shah M.H.
        • Goldner W.S.
        • Halfdanarson T.R.
        • et al.
        NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018.
        J Natl Compr Canc Netw. 2018; 16: 693-702
        • Caplin M.E.
        • Pavel M.
        • Ćwikła J.B.
        • et al.
        Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
        N Engl J Med. 2014; 371: 224-233
        • Rinke A.
        • Müller H.H.
        • Schade-Brittinger C.
        • et al.
        Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
        J Clin Oncol. 2009; 27: 4656-4663
        • Bongiovanni A.
        • Recine F.
        • Riva N.
        • et al.
        Outcome analysis of first-line somatostatin analog treatment in metastatic pulmonary neuroendocrine tumors and prognostic significance of (18)FDG-PET/CT.
        Clin Lung Cancer. 2017; 18: 415-420
        • Sullivan I.
        • Le Teuff G.
        • Guigay J.
        • et al.
        Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
        Eur J Cancer. 2017; 75: 259-267
        • Yao J.C.
        • Fazio N.
        • Singh S.
        • et al.
        Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.
        Lancet. 2016; 387: 968-977
        • Fazio N.
        • Buzzoni R.
        • Delle Fave G.
        • et al.
        Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
        Cancer Sci. 2018; 109: 174-181
        • Hirmas N.
        • Jadaan R.
        • Al-Ibraheem A.
        Peptide receptor radionuclide therapy and the treatment of gastroentero-pancreatic neuroendocrine tumors: current findings and future perspectives.
        Nucl Med Mol Imaging. 2018; 52: 190-199
        • Hope T.A.
        • Bodei L.
        • Chan J.A.
        • et al.
        NANETS/SNMMI consensus statement on patient selection and appropriate use of (177)Lu-DOTATATE peptide receptor radionuclide therapy.
        J Nucl Med. 2020; 61: 222-227
        • Bodei L.
        • Mueller-Brand J.
        • Baum R.P.
        • et al.
        The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
        Eur J Nucl Med Mol Imaging. 2013; 40: 800-816
        • Strosberg J.
        • El-Haddad G.
        • Wolin E.
        • et al.
        Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors.
        N Engl J Med. 2017; 376: 125-135
        • Strosberg J.R.
        • Caplin M.E.
        • Kunz P.L.
        • et al.
        (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.
        Lancet Oncol. 2021; 22: 1752-1763
        • Sabet A.
        • Haug A.R.
        • Eiden C.
        • et al.
        Efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in metastatic pulmonary neuroendocrine tumors: a dual-centre analysis.
        Am J Nucl Med Mol Imaging. 2017; 7: 74-83
        • Parghane R.V.
        • Talole S.
        • Prabhash K.
        • et al.
        Clinical response profile of metastatic/advanced pulmonary neuroendocrine tumors to peptide receptor radionuclide therapy with 177Lu-DOTATATE.
        Clin Nucl Med. 2017; 42: 428-435
        • Brabander T.
        • van der Zwan W.A.
        • Teunissen J.J.M.
        • et al.
        Long-Term efficacy, survival, and safety of [(177)Lu-DOTA(0),Tyr(3)]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors.
        Clin Cancer Res. 2017; 23: 4617-4624
        • Mirvis E.
        • Toumpanakis C.
        • Mandair D.
        • et al.
        Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
        Lung Cancer. 2020; 150: 70-75